Physician profile
Beth A Sandy
NPI 1689735581
$924,110.35
in general payments reported to CMS, 2019-2025
20 companies · $215K in 2025
The $215K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157K · 2022: $162K · 2023: $193K · 2024: $196K · 2025: $215K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $426K · Travel and Lodging: $141K · Food and Beverage: $20K · Consulting Fee: $14K · Honoraria: $3,850 · Education: $4.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $425,695.00 |
| Travel and Lodging | $141,105.79 |
| Food and Beverage | $20,183.38 |
| Consulting Fee | $13,745.00 |
| Honoraria | $3,850.00 |
| Education | $4.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $486,885.96 | 2021-2025 | Imfinzi, Tagrisso, Datroway |
| Amgen INC. | $123,054.58 | 2021-2025 | Lumakras, Imdelltra (Amg757), Imdelltra (Amg 757) |
| Jazz Pharmaceuticals INC. | $120,758.42 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75,000.31 | 2021-2024 | Alunbrig, Exkivity |
| Lilly USA, LLC | $49,785.42 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $32,606.02 | 2021-2025 | Keytruda |
| Janssen Biotech, INC. | $22,348.85 | 2022-2025 | Rybrevant, Carvykti |
| Catalyst Pharmaceuticals, INC. | $5,005.99 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,093.31 | 2021-2022 | |
| Abbvie INC. | $2,050.00 | 2023-2025 | |
| Pfizer INC. | $1,318.54 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $1,055.00 | 2022 | |
| Nuvation Bio INC. | $720.00 | 2025 | Ibtrozi |
| Mirati Therapeutics, INC. | $124.99 | 2023 | Krazati |
| Daiichi Sankyo INC. | $84.45 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $79.53 | 2023-2024 | Optune, Optune Lua (Novottf-200t) |
| Genentech USA, INC. | $64.48 | 2021-2024 | Alecensa, Tecentriq, Gavreto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.08 | 2021 | |
| Caris Mpi, INC. | $29.24 | 2025 | Mi Cancer Seek |
| Hologic Sales and Service, LLC | $14.18 | 2023 | Coolseal Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Sandy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.